SCHEMBL14979754

SCHEMBL14979754

C=CC(=O)Nc1cccc(C(=O)Nc2ccc(Nc3nccc(-c4cnc5[nH]ccc5c4)n3)cc2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 3/20 0.56
▸ ITK Q08881 2/20 0.56
▸ PDGFRA P16234 4/20 0.55
▸ MAPK10 P53779 4/20 0.55
▸ IRAK1 P51617 3/20 0.55
▸ MAPK8 P45983 3/20 0.55
▸ MAPK9 P45984 3/20 0.55
▸ JAK2 O60674 3/20 0.53
▸ JAK3 P52333 3/20 0.53
▸ JAK1 P23458 2/20 0.53
▸ TYK2 P29597 2/20 0.53
▸ PIP4K2A P48426 2/20 0.51
▸ PIP4K2B P78356 2/20 0.51
▸ ABL1 P00519 3/20 0.51
▸ BCR P11274 3/20 0.51
▸ SRC P12931 3/20 0.51
▸ PRKCA P17252 3/20 0.51
▸ PRKCD Q05655 3/20 0.51
▸ PDGFRB P09619 2/20 0.51
▸ EGFR P00533 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14979755 0.93 PDGFRA (0.59) BTKITKPDGFRAMAPK10MAPK8
SCHEMBL29644767 0.85 PDGFRA (0.73) BTKITKPDGFRAMAPK10IRAK1
SCHEMBL14979760 0.85 PDGFRA (0.73) BTKITKPDGFRAMAPK10IRAK1
SCHEMBL14979759 0.79 PDGFRA (0.77) BTKITKPDGFRAMAPK10IRAK1
SCHEMBL18313107 0.79 CDK7 (0.76) BTKMAPK8MAPK9PIP4K2APIP4K2B
SCHEMBL14979753 0.78 PDGFRA (0.79) BTKITKPDGFRAMAPK10IRAK1
SCHEMBL18346151 0.76 CDK7 (0.56) BTKITKPDGFRAIRAK1JAK3
SCHEMBL16176428 0.76 CDK8 (0.71) BTKITKPDGFRAIRAK1MAPK8
SCHEMBL3247127 0.75 PIKFYVE (0.62) PDGFRAABL1BCRPRKCAPDGFRB
SCHEMBL14979771 0.73 MAPK8 (0.77) PDGFRAMAPK10IRAK1MAPK8MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220153730-A9 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-05-19 — — US disclosed
US-20210300911-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-09-30 — — US disclosed
US-10981903-B2 Inhibitors of c-Jun-N-terminal kinase (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-04-20 — — US disclosed
US-20200087295-A9 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-03-19 — — US disclosed
EP-3569598-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) Dana Farber Cancer Institute, Inc. (US) 2019-11-20 — — EP disclosed
US-20190248778-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-08-15 — — US disclosed
EP-2822935-B1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) DANA FARBER CANCER INST INC (US) 2019-05-15 — — EP disclosed
US-20160368910-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-12-22 — — US disclosed
US-20160368910-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-12-22 — — US disclosed
US-9382239-B2 Inhibitors of c-Jun-N-terminal kinase (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-07-05 — — US disclosed
US-9382239-B2 Inhibitors of c-Jun-N-terminal kinase (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-07-05 — — US disclosed
US-20140309249-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) Dana-Farber Cancer Intitute, Inc. (US) 2014-10-16 — — US disclosed
US-20140309249-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) Dana-Farber Cancer Intitute, Inc. (US) 2014-10-16 — — US disclosed
WO-2013074986-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2013-05-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10981903-B2 Inhibitors of c-Jun-N-terminal kinase (JNK) CNKSR1, MAPK1, MAP3K1 BTK 1911/4885ITK 2173/4885PDGFRA 2050/4885
US-20210300911-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) CNKSR1, MAPK1, MAP3K1 BTK 1911/4885ITK 2173/4885PDGFRA 2050/4885
US-20200087295-A9 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) CNKSR1, MAPK1, MAP3K1 BTK 1911/4885ITK 2173/4885PDGFRA 2050/4885
US-20220153730-A9 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) CNKSR1, MAPK1, MAP3K1 BTK 1911/4885ITK 2173/4885PDGFRA 2050/4885
US-20160368910-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) CNKSR1, MAPK1, MAP3K1 BTK 1911/4885ITK 2173/4885PDGFRA 2050/4885
US-20140309249-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) CNKSR1, MAPK1, MAP3K1 BTK 1911/4885ITK 2173/4885PDGFRA 2050/4885
US-20190248778-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) CNKSR1, MAPK1, MAP3K1 BTK 1911/4885ITK 2173/4885PDGFRA 2050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback